Key corporate developments:
Insilico Medicine (03696) plans to participate in the establishment of an investment fund. China Power (02380) intends to sell a 24.8726% stake in Qixin Power to Contemporary Amperex Technology (CATL) for 2.2557 billion yuan. Harbour BioMed-B (02142) has received approval from the National Medical Products Administration for its new drug clinical trial application for HBM7004, which is intended for the treatment of advanced solid tumors. Lopal Technology (02465) plans to inject 1.4 billion yuan into Changzhou Lithium Source. Xunfei Medical Technology (02506) has had its Wind ESG rating upgraded to AA level.
Business performance highlights:
Xiaomi Group-W (01810) reported second-quarter revenue of approximately 108.922 billion yuan, representing a 9.9% increase quarter-on-quarter, with continued escalation in hardcore technology R&D investment. GigaDevice (03986) released its interim results, posting a net profit attributable to shareholders of 6.857 billion yuan, a substantial year-on-year surge of 1091.5%. Baidu Group-SW (09888) announced its second-quarter results, with net profit attributable to Baidu reaching 2.319 billion yuan, while its intelligent cloud infrastructure maintained robust growth momentum. Guotai Haitong (02611) published its interim results, recording a net profit attributable to shareholders of 20.26 billion yuan, an increase of 28.74% year-on-year. China Unicom (00762) released its interim results, with profit attributable to shareholders standing at 9.5 billion yuan, a decrease of 34.6% year-on-year, although operating cash flow reached a new high in recent years. Fuyao Glass (03606) reported interim results with profit attributable to shareholders of 3.97 billion yuan, down 17.37% year-on-year. Huaneng Power International (00902) announced its interim results, with net profit attributable to shareholders of approximately 6.586 billion yuan, a 28.89% decrease year-on-year. CSC Financial (06066) released its interim results, showing a net profit attributable to shareholders of 7.639 billion yuan, up 69.44% year-on-year. Pony AI-W (02026) posted interim results with total revenue of 70.47 million US dollars, representing a year-on-year increase of 98.88%. Hesai-W (02525) reported second-quarter results, with net profit of 70.6 million yuan, up 60% year-on-year. DKSH Holding (02419) released its interim results, achieving operating revenue of 10.089 billion yuan, focusing on technological innovation in farming to build core cost-reduction barriers. Ping An Good Doctor (01833) published its interim results, with net profit attributable to shareholders of 219 million yuan, an increase of 63.5% year-on-year, while its corporate health management business GMV exceeded 1.79 billion yuan. Weimob Group (02013) released its interim results, generating revenue of 869 million yuan, up 12.1% year-on-year, continuing to consolidate its leading position on the Tencent channel while advancing its multi-platform strategy.